Trade Mark Journal No.2026/039 25 September 2026

UK00004445014 14 September 2026 (5,42)

WE NUKE CANCER

International priority date claimed: 12 March 2026 (United States of America) (99698638)

Class 5: Medicinal preparations for use in oncology; pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders; radiopharmaceutical preparations for the treatment of cancer.
Class 42: Scientific research and development; Pharmaceutical research and development; Research and development of antibodies; Research and development of medicines; Research and development of new products; Research and development of conjugated antibodies; Research and development in the field of pharmaceuticals; Research and development of advanced learning technologies and teaching methods; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer.

Actinium Pharmaceuticals, Inc.

Representative: Dentons UK and Middle East LLP